These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11175372)

  • 1. Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.
    Halter JA; Blight AR; Donovan WH; Calvillo O
    Spinal Cord; 2000 Dec; 38(12):728-32. PubMed ID: 11175372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous infusion of 4-AP in chronic spinal cord injured subjects.
    Donovan WH; Halter JA; Graves DE; Blight AR; Calvillo O; McCann MT; Sherwood AM; Castillo T; Parsons KC; Strayer JR
    Spinal Cord; 2000 Jan; 38(1):7-15. PubMed ID: 10762192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid concentrations of 4-aminopyridine following intravenous injection and metered intrathecal delivery in canines.
    Pratt K; Toombs JP; Widmer WR; Borgens RB
    J Neurotrauma; 1995 Feb; 12(1):23-39. PubMed ID: 7783231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
    Grijalva I; Guízar-Sahagún G; Castañeda-Hernández G; Mino D; Maldonado-Julián H; Vidal-Cantú G; Ibarra A; Serra O; Salgado-Ceballos H; Arenas-Hernández R
    Pharmacotherapy; 2003 Jul; 23(7):823-34. PubMed ID: 12885095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial.
    Segal JL; Pathak MS; Hernandez JP; Himber PL; Brunnemann SR; Charter RS
    Pharmacotherapy; 1999 Jun; 19(6):713-23. PubMed ID: 10391417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
    Hansebout RR; Blight AR; Fawcett S; Reddy K
    J Neurotrauma; 1993; 10(1):1-18. PubMed ID: 8320728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial.
    Wolfe DL; Hayes KC; Hsieh JT; Potter PJ
    J Neurotrauma; 2001 Aug; 18(8):757-71. PubMed ID: 11526982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
    Hayes KC; Potter PJ; Hsieh JT; Katz MA; Blight AR; Cohen R
    Arch Phys Med Rehabil; 2004 Jan; 85(1):29-34. PubMed ID: 14970964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 4-Aminopyridine for the Management of Spasticity in Spinal Cord Injury: A Systematic Review.
    Wiener J; Hsieh J; McIntyre A; Teasell R
    Top Spinal Cord Inj Rehabil; 2018; 24(4):353-362. PubMed ID: 30459498
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
    Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
    J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases.
    Potter PJ; Hayes KC; Hsieh JT; Delaney GA; Segal JL
    Spinal Cord; 1998 Mar; 36(3):147-55. PubMed ID: 9554012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Cardenas DD; Ditunno J; Graziani V; Jackson AB; Lammertse D; Potter P; Sipski M; Cohen R; Blight AR
    Spinal Cord; 2007 Feb; 45(2):158-68. PubMed ID: 16773037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.
    Hayes KC; Potter PJ; Hansebout RR; Bugaresti JM; Hsieh JT; Nicosia S; Katz MA; Blight AR; Cohen R
    Clin Neuropharmacol; 2003; 26(4):185-92. PubMed ID: 12897638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High doses of 4-aminopyridine improve functionality in chronic complete spinal cord injury patients with MRI evidence of cord continuity.
    Grijalva I; García-Pérez A; Díaz J; Aguilar S; Mino D; Santiago-Rodríguez E; Guizar-Sahagún G; Castañeda-Hernández G; Maldonado-Julián H; Madrazo I
    Arch Med Res; 2010 Oct; 41(7):567-75. PubMed ID: 21167397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury.
    Isoda WC; Segal JL
    Pharmacotherapy; 2003 Feb; 23(2):133-6. PubMed ID: 12587799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury.
    Segal JL; Brunnemann SR
    Pharmacotherapy; 1997; 17(3):415-23. PubMed ID: 9165545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
    Lim JH; Muguet-Chanoit AC; Smith DT; Laber E; Olby NJ
    PLoS One; 2014; 9(12):e116139. PubMed ID: 25551385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric emptying effect by 4-aminopyridine in patients with chronic spinal cord injury.
    Grijalva I; Guízar-Sahagún G; Rodríguez-Pacheco D; Francisco-Argüelles C; Castañeda-Hernández G; Palma-Aguirre JA
    Arch Med Res; 2007 May; 38(4):392-7. PubMed ID: 17416285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal pressure monitoring and cerebrospinal fluid drainage in acute spinal cord injury: a prospective randomized trial.
    Kwon BK; Curt A; Belanger LM; Bernardo A; Chan D; Markez JA; Gorelik S; Slobogean GP; Umedaly H; Giffin M; Nikolakis MA; Street J; Boyd MC; Paquette S; Fisher CG; Dvorak MF
    J Neurosurg Spine; 2009 Mar; 10(3):181-93. PubMed ID: 19320576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans.
    Segal JL; Brunnemann SR
    J Spinal Cord Med; 1998 Jul; 21(3):200-4. PubMed ID: 9863929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.